Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01535950 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01535950 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 43 participants.
The verdict
NCT01535950, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.
Interventions
- DRUG Placebo
- DRUG LFG316
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01535950
The ClinicalTrials.gov registry entry for NCT01535950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01535950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01535950 about?
NCT01535950 is a clinical study titled "Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)". This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.
What is the current status of trial NCT01535950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2012-02. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01535950?
The interventions under investigation include: Placebo (DRUG), LFG316 (DRUG).
Who is sponsoring clinical trial NCT01535950?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.